Global Iodine Deficiency Drug Market – Industry Trends and Forecast to 2028

Market Analysis and Insights : Global Iodine Deficiency Drug Market

The iodine deficiency drug market is expected to gain market growth at a potential rate of 6% in the forecast period of 2021 to 2028. Growing of the population is the vital factor escalating the market growth.

Iodine deficiency disorders are the rare endocrinology disorders in which the thyroid gland present in the neck produces inadequate amount or is not capable of producing thyroid hormone because of the deficiency of iodine as it is essential nutrients mandatory for the development of thyroid to be functional. Thyroid hormone is the reason for regulating the body’s temperature, metabolism and the heart rate. The patients with iodine deficiency experience abnormal brain development, mental retardation psychomotor defects and hearing and speech impairment.

Major factors that are expected to boost the growth of the iodine deficiency drug market in the forecast period are the growing of the incidences of goitre and hypothyroidism disorders around the world, the rising of the population who are susceptible to iodine deficiency and the swift adoption of newer formulations and the novel dosage forms. On the other hand, the active treatment is either unavailable or unaffordable, and the insufficient amount of awareness regarding the iodine deficiency in some advancing nations are further anticipated to impede the growth of the iodine deficiency drug market in the near future.

The iodine deficiency drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the iodine deficiency drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Iodine Deficiency Drug Market Scope and Market Size

The iodine deficiency drug market is segmented on the basis of therapy type, treatment type, dosage form type, route of administration and end users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• Based on the therapy type, the iodine deficiency drug market is segmented into thyroid hormone replacement therapy and radioactive iodine therapy.
• Based on the treatment type, the iodine deficiency drug market is segmented into medication, surgery, radioactive iodine and iodine supplements. Medication is further sub segmented into L-thyroxine agonist and levothyroxine. Surgery is further sub segmented into thyroidectomy.
• Based on the dosage form type, the iodine deficiency drug market is segmented into tablet, capsule, solution and powder.
• Based on the route of administration, the iodine deficiency drug market is segmented into oral and injectable.
• Based on the end users, the iodine deficiency drug market is segmented into hospitals, homecare, specialty clinics, others.

Iodine Deficiency Drug Market Country Level Analysis

The iodine deficiency drug market is analysed and market size information is provided by country, therapy type, treatment type, dosage form type, route of administration and end users as referenced above.

The countries covered in the iodine deficiency drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America Dominates the iodine deficiency drug market because of the growing of the healthcare infrastructure. Furthermore, the growing awareness regarding the iodine deficiency will further boost the growth of the iodine deficiency market in the region during the forecast period. Asia Pacific is projected to observe significant amount of growth in the iodine deficiency drug market because of the of the research and development initiatives. Moreover, the rising of the population is further anticipated to propel the growth of the iodine deficiency drug market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The iodine deficiency drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Iodine Deficiency Drug Market Share Analysis

The iodine deficiency drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to iodine deficiency drug market.

The major players covered in the iodine deficiency drug market report are Sanofi, Johnson & Johnson Services, Inc., Biotex Inc., Apitope Technology (Bristol) Ltd, Novartis AG, Immunovant, Inc., Abbott, Bayer AG, ILDONG PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc., Merck KGaA, Titan Pharmaceuticals, Inc., Synthonics, Inc., Genexine, Inc., Lupin Pharmaceuticals, Inc., Alvogen., AbbVie Inc., King Pharma, Fresenius Kabi AG, Mylan N.V., F. Hoffmann La Roche Ltd, Lilly, Pfizer Inc., Novo Nordisk A/S, AstraZeneca, Astellas Pharma Inc., among other domestic and global players. Iodine deficiency drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-42543